688739 成大生物
交易中 10-09 11:24:14
资讯
新帖
简况
股市必读：成大生物新发布《辽宁成大生物股份有限公司2026年第二次临时股东会会议资料》
证券之星 · 10-08 03:29
股市必读：成大生物新发布《辽宁成大生物股份有限公司2026年第二次临时股东会会议资料》
成大生物：加快新产品商业化落地
证券之星 · 09-30
成大生物：加快新产品商业化落地
成大生物（688739）披露关于变更回购股份用途并注销暨减少注册资本的议案，9月24日股价下跌1.43%
证券之星 · 09-24
成大生物（688739）披露关于变更回购股份用途并注销暨减少注册资本的议案，9月24日股价下跌1.43%
成大生物最新公告：签订重组四价肠道病毒疫苗技术转让合同
证券之星 · 09-24
成大生物最新公告：签订重组四价肠道病毒疫苗技术转让合同
股市必读：成大生物新发布《辽宁成大生物股份有限公司高级管理人员减持股份计划时间届满暨减持结果的公告》
证券之星 · 09-23
股市必读：成大生物新发布《辽宁成大生物股份有限公司高级管理人员减持股份计划时间届满暨减持结果的公告》
每周股票复盘：成大生物（688739）Q2营收增15.94%
证券之星 · 08-30
每周股票复盘：成大生物（688739）Q2营收增15.94%
成大生物：公司全资子公司上海成大致远医药科技有限公司已完成工商注册
证券之星 · 08-28
成大生物：公司全资子公司上海成大致远医药科技有限公司已完成工商注册
成大生物：2026年上半年实现营业收入6.77亿元
证券之星 · 08-28
成大生物：2026年上半年实现营业收入6.77亿元
成大生物：公司核心产品Vero狂犬疫苗国内销量止跌回升
证券之星 · 08-28
成大生物：公司核心产品Vero狂犬疫苗国内销量止跌回升
股市必读：成大生物中报 - 第二季度单季净利润同比下降29.73%
证券之星 · 08-26
股市必读：成大生物中报 - 第二季度单季净利润同比下降29.73%
成大生物（688739）2026年中报简析：净利润同比下降72.79%
证券之星 · 08-26
成大生物（688739）2026年中报简析：净利润同比下降72.79%
成大生物(688739)6月30日股东户数2.3万户，较上期减少4.11%
证券之星 · 08-25
成大生物(688739)6月30日股东户数2.3万户，较上期减少4.11%
图解成大生物中报：第二季度单季净利润同比下降29.73%
证券之星 · 08-25
图解成大生物中报：第二季度单季净利润同比下降29.73%
股市必读：成大生物新发布《辽宁成大生物股份有限公司董事会审计委员会关于公司治理专项核查结果的公告》
证券之星 · 08-24
股市必读：成大生物新发布《辽宁成大生物股份有限公司董事会审计委员会关于公司治理专项核查结果的公告》
每周股票复盘：成大生物（688739）治理专项核查结果公布
证券之星 · 08-23
每周股票复盘：成大生物（688739）治理专项核查结果公布
成大生物（688739）披露公司治理专项核查结果公告，8月20日股价上涨7.22%
证券之星 · 08-20
成大生物（688739）披露公司治理专项核查结果公告，8月20日股价上涨7.22%
股市必读：成大生物（688739）8月18日董秘有最新回复
证券之星 · 08-19
股市必读：成大生物（688739）8月18日董秘有最新回复
成大生物：截至2025年末，在职员工1781人
证券之星 · 08-18
成大生物：截至2025年末，在职员工1781人
成大生物：公司正稳步推进疫苗与创新药双轮驱动战略布局
证券之星 · 08-18
成大生物：公司正稳步推进疫苗与创新药双轮驱动战略布局
成大生物(688739.SH)：流感病毒裂解疫苗(高剂量)进入I期临床试验
智通财经 · 07-17
成大生物(688739.SH)：流感病毒裂解疫苗(高剂量)进入I期临床试验
加载更多
公司概况
公司名称：
辽宁成大生物股份有限公司
所属行业：
医药制造业
上市日期：
2021-10-28
主营业务：
辽宁成大生物股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是人用狂犬病疫苗、人用乙脑灭活疫苗。
发行价格：
110.00
{"stockData":{"symbol":"688739","market":"SH","secType":"STK","nameCN":"成大生物","latestPrice":20.9,"timestamp":1791516254000,"preClose":20.89,"halted":0,"volume":1273981,"delay":0,"changeRate":0.0005,"floatShares":416000000,"shares":416000000,"eps":0.1028,"marketStatus":"交易中","change":0.01,"latestTime":"10-09 11:24:14","open":20.81,"high":21.03,"low":20.68,"amount":26646100,"amplitude":0.0168,"askPrice":20.9,"askSize":3,"bidPrice":20.88,"bidSize":22,"shortable":0,"etf":0,"ttmEps":0.1028,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1791516600000},"marketStatusCode":2,"adr":0,"adjPreClose":20.89,"symbolType":"stock_kcb","openAndCloseTimeList":[[1791509400000,1791516600000],[1791522000000,1791529200000]],"highLimit":22.98,"lowLimit":18.8,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":416450000,"isCdr":false,"pbRate":0.93,"roa":"--","peRate":203.307393,"roe":"0.36%","epsLYR":0.32,"committee":-0.144444,"marketValue":8704000000,"turnoverRate":0.0031,"status":0,"floatMarketCap":8704000000},"requestUrl":"/m/hq/s/688739/","defaultTab":"news","newsList":[{"id":"2673782017","title":"股市必读：成大生物新发布《辽宁成大生物股份有限公司2026年第二次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673782017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673782017?lang=zh_cn&edition=full","pubTime":"2026-10-08 03:29","pubTimestamp":1791401350,"startTime":"0","endTime":"0","summary":"公司公告汇总辽宁成大生物股份有限公司2026年第二次临时股东会会议资料辽宁成大生物股份有限公司拟将已回购的2,982,382股股份用途由用于员工持股计划或股权激励变更为注销并减少注册资本，公司总股本将由416,450,000股减至413,467,618股；同时修订《公司章程》中关于注册资本、股份总数及经营范围表述，并提请股东大会审议；拟续聘致同会计师事务所为2026年度财务及内部控制审计机构，审计费用预计不超过70万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800001657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","BK0250","BK0188","BK0046","BK0077","BK0239","688739","BK0074","BK0012","BK0185","600739","BK0144","600201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671279929","title":"成大生物：加快新产品商业化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2671279929","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671279929?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:36","pubTimestamp":1790753819,"startTime":"0","endTime":"0","summary":"证券之星消息，成大生物09月30日在投资者关系平台上答复投资者关心的问题。请正面回复，不要官话套话，请在档次为人的层次层面回答问题成大生物回复：尊敬的投资者，您好！对此，公司董事会已专题研究部署：一是加快新产品商业化落地，三价及四价流感疫苗相继获批上市，人用二倍体狂犬疫苗自 9 月起上市销售；公司Vero 细胞狂犬疫苗国内销量企稳回升、出口同比增长。二是落实投资者回报，持续推进现金分红与股份回购，维护股东权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000019614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499556","title":"成大生物（688739）披露关于变更回购股份用途并注销暨减少注册资本的议案，9月24日股价下跌1.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499556","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669499556?lang=zh_cn&edition=full","pubTime":"2026-09-24 22:28","pubTimestamp":1790260103,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，成大生物报收于20.62元，较前一交易日下跌1.43%，最新总市值为85.87亿元。会议审议《关于变更回购股份用途并注销暨减少注册资本的议案》《关于修订<公司章程>的议案》《关于续聘会计师事务所的议案》。其中，《关于变更回购股份用途并注销暨减少注册资本的议案》为特别决议议案，并对中小投资者单独计票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400041429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669469478","title":"成大生物最新公告：签订重组四价肠道病毒疫苗技术转让合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2669469478","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669469478?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:49","pubTimestamp":1790243349,"startTime":"0","endTime":"0","summary":"成大生物(688739.SH)公告称，公司与维尔泰克签署《重组四价肠道病毒疫苗技术转让合同》，受让重组四价肠道病毒疫苗(汉逊酵母)项目全部权益，技术转让费4600万元(含税)，依据里程碑分期支付；销售提成及销售里程碑奖励根据产品上市后销售情况支付。标的产品尚处研发早期阶段，后续临床试验、注册审批及商业化存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400031285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","159646","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669129146","title":"股市必读：成大生物新发布《辽宁成大生物股份有限公司高级管理人员减持股份计划时间届满暨减持结果的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669129146","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669129146?lang=zh_cn&edition=full","pubTime":"2026-09-23 01:50","pubTimestamp":1790099425,"startTime":"0","endTime":"0","summary":"公司公告汇总辽宁成大生物股份有限公司高级管理人员减持股份计划时间届满暨减持结果的公告辽宁成大生物股份有限公司副总经理陈新先生原计划自2026年6月22日至9月21日通过集中竞价方式减持公司股份不超过131,000股，占公司总股本比例不超过0.03%。本次减持计划未设置最低减持数量和比例，实际减持情况与此前披露的计划一致，未违反相关法律法规及承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002347.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0185","688739","BK0196","600201","BK0077","BK0074","BK0239","BK0046","BK0250","BK0028","BK0144","600739","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663456530","title":"每周股票复盘：成大生物（688739）Q2营收增15.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663456530","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663456530?lang=zh_cn&edition=full","pubTime":"2026-08-30 09:42","pubTimestamp":1788054131,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，成大生物报收于21.08元，较上周的20.68元上涨1.93%。本周，成大生物8月26日盘中最高价报21.46元。业绩披露要点：2026年第二季度主营收入4.04亿元，同比上升15.94%。股本股东变化截至2026年6月30日，公司股东户数为2.3万户，较3月31日减少987户，减幅4.11%。第二季度单季主营收入4.04亿元，同比上升15.94%；单季归母净利润3518.83万元，同比下降29.73%；单季扣非净利润3719.85万元，同比下降5.62%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662063033","title":"成大生物：公司全资子公司上海成大致远医药科技有限公司已完成工商注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2662063033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662063033?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:16","pubTimestamp":1787908562,"startTime":"0","endTime":"0","summary":"成大生物回复：尊敬的投资者您好：公司联合控股股东辽宁成大共同发起设立成大（大连）生物医药产业投资基金，基金总规模不超过10亿元，首期规模5.02亿元，已完成工商注册及私募基金备案。公司全资子公司上海成大致远医药科技有限公司已完成工商注册，创新药战略布局有序落地。若发生相关重大进展，公司将严格遵照监管规则及信息披露相关规定，通过法定信息披露渠道及时履行信息披露义务，敬请您关注公司公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800039434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","09939","BK1161","BK1574","BK1515","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662006303","title":"成大生物：2026年上半年实现营业收入6.77亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662006303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662006303?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:16","pubTimestamp":1787908560,"startTime":"0","endTime":"0","summary":"证券之星消息，成大生物08月28日在投资者关系平台上答复投资者关心的问题。公司核心狂犬疫苗产品毛利率长期在90%以上，批签发数量位居行业前列。成大生物回复：尊敬的投资者您好：2026年上半年，公司实现营业收入6.77亿元，归属于母公司所有者净利润3,328.06万元。利润降幅大于营收，主要受增值税税收政策调整影响，营业成本费用上升、毛利率下滑等多重因素叠加所致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800039430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662063771","title":"成大生物：公司核心产品Vero狂犬疫苗国内销量止跌回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662063771","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662063771?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:15","pubTimestamp":1787908558,"startTime":"0","endTime":"0","summary":"公司核心产品Vero狂犬疫苗国内销量止跌回升，出口同比增长11.50%；人用二倍体狂犬疫苗、三价/四价流感疫苗等新产品相继获批上市，创新药产业基金布局有序推进。后续公司将持续提升经营质量，统筹业务发展与股东回报，力争以良好业绩回报广大投资者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800039425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688739","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662075075","title":"股市必读：成大生物中报 - 第二季度单季净利润同比下降29.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662075075","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662075075?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:42","pubTimestamp":1787697763,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年中报显示归母净利润3328.06万元，同比下降72.79%；第二季度单季度归母净利润3518.83万元，同比下降29.73%。上半年实现营业收入67,726.58万元，净利润3,328.06万元；核心产品人用狂犬病疫苗出口增长11.50%；完成AI+疫苗研发联合实验室建设；实施股份回购并完成现金分红；持续优化治理结构，加强信息披露与投资者沟通。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600011637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662381750","title":"成大生物（688739）2026年中报简析：净利润同比下降72.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662381750","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662381750?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:17","pubTimestamp":1787696271,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期成大生物发布2026年中报。根据财报显示，成大生物净利润同比下降72.79%。截至本报告期末，公司营业总收入6.77亿元，同比下降4.18%，归母净利润3328.06万元，同比下降72.79%。按单季度数据看，第二季度营业总收入4.04亿元，同比上升15.94%，第二季度归母净利润3518.83万元，同比下降29.73%。去年的净利率为9.48%，算上全部成本后，公司产品或服务的附加值一般。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600009666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662386057","title":"成大生物(688739)6月30日股东户数2.3万户，较上期减少4.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662386057","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662386057?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:42","pubTimestamp":1787650932,"startTime":"0","endTime":"0","summary":"证券之星消息，近日成大生物披露，截至2026年6月30日公司股东户数为2.3万户，较3月31日减少987.0户，减幅为4.11%。在生物制品行业个股中，成大生物股东户数低于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.55万户。从股价来看，2026年3月31日至2026年6月30日，成大生物区间跌幅为20.46%，在此期间股东户数减少987.0户，减幅为4.11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500036890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662920314","title":"图解成大生物中报：第二季度单季净利润同比下降29.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662920314","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662920314?lang=zh_cn&edition=full","pubTime":"2026-08-25 02:38","pubTimestamp":1787596730,"startTime":"0","endTime":"0","summary":"证券之星消息，成大生物2026年中报显示，上半年度公司主营收入6.77亿元，同比下降4.18%；归母净利润3328.06万元，同比下降72.79%；扣非净利润2683.34万元，同比下降73.69%；其中2026年第二季度，公司单季度主营收入4.04亿元，同比上升15.94%；单季度归母净利润3518.83万元，同比下降29.73%；单季度扣非净利润3719.85万元，同比下降5.62%；负债率3.68%，投资收益1840.8万元，财务费用-474.92万元，毛利率74.24%。财报数据概要请见下图:本文数据来源于成大生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500005545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661245486","title":"股市必读：成大生物新发布《辽宁成大生物股份有限公司董事会审计委员会关于公司治理专项核查结果的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661245486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661245486?lang=zh_cn&edition=full","pubTime":"2026-08-24 03:22","pubTimestamp":1787512932,"startTime":"0","endTime":"0","summary":"公司公告汇总辽宁成大生物股份有限公司董事会审计委员会关于公司治理专项核查结果的公告辽宁成大生物股份有限公司董事会审计委员会组织开展了公司治理专项核查，核查范围包括募集资金投资项目管理、研发支出资本化等事项。容诚会计师事务所作为独立第三方实施核查并出具报告，董事会审计委员会确认核查程序完备、结论客观。核查结果显示，相关事项符合监管规定和公司内控制度要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400001403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0077","600201","BK0074","BK0250","BK0144","688739","BK0196","BK0028","600739","BK0185","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661143362","title":"每周股票复盘：成大生物（688739）治理专项核查结果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2661143362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661143362?lang=zh_cn&edition=full","pubTime":"2026-08-23 03:21","pubTimestamp":1787426469,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，成大生物报收于20.68元，较上周的20.86元下跌0.86%。本周，成大生物8月20日盘中最高价报22.3元。公司公告汇总辽宁成大生物股份有限公司董事会审计委员会发布关于公司治理专项核查结果的公告，确认已对募集资金投资项目管理、研发支出资本化等事项完成核查。容诚会计师事务所作为独立第三方出具报告，核查程序完备、结论客观。结果显示，相关事项符合监管规定与公司内控制度要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660823813","title":"成大生物（688739）披露公司治理专项核查结果公告，8月20日股价上涨7.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660823813","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660823813?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:32","pubTimestamp":1787236336,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘，成大生物报收于21.54元，较前一交易日上涨7.22%，最新总市值为89.7亿元。近日，辽宁成大生物股份有限公司发布《董事会审计委员会关于公司治理专项核查结果的公告》。公告显示，公司董事会审计委员会组织开展了公司治理专项核查，核查范围包括募集资金投资项目管理、研发支出资本化等事项。容诚会计师事务所作为独立第三方实施核查并出具报告，董事会审计委员会确认核查程序完备、结论客观。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000045589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660494350","title":"股市必读：成大生物（688739）8月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660494350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660494350?lang=zh_cn&edition=full","pubTime":"2026-08-19 03:26","pubTimestamp":1787081172,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，成大生物报收于20.44元，下跌1.11%，换手率0.32%，成交量1.32万手，成交额2703.57万元。董秘最新回复投资者： 请问上市公司在生物制药及创新药方面投资进展如何，关于公司“疫苗＋创新药”布局的近期有何计划？研读公司 2024 至 2025 年年报，员工规模同比下降 1.44%，人均营业收入下滑 15.85%，两项指标同步回落。截至2025年末，公司在职员工1781人，较2024年减少26人，报告期内人员变化系正常人员流动，并非主动人员精简。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900003473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660463595","title":"成大生物：截至2025年末，在职员工1781人","url":"https://stock-news.laohu8.com/highlight/detail?id=2660463595","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660463595?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:45","pubTimestamp":1787042712,"startTime":"0","endTime":"0","summary":"证券之星消息，成大生物08月18日在投资者关系平台上答复投资者关心的问题。研读公司 2024 至 2025 年年报，员工规模同比下降 1.44%，人均营业收入下滑 15.85%，两项指标同步回落。截至2025年末，公司在职员工1781人，较2024年减少26人，报告期内人员变化系正常人员流动，并非主动人员精简。公司已建立由固定薪酬和绩效薪酬构成的薪酬体系，并通过企业年金、福利补贴、补充保险等措施增强员工获得感和核心人才稳定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800028730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660246335","title":"成大生物：公司正稳步推进疫苗与创新药双轮驱动战略布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2660246335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660246335?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:36","pubTimestamp":1787042185,"startTime":"0","endTime":"0","summary":"公司正稳步推进疫苗与创新药双轮驱动战略布局。公司将持续巩固疫苗主业，依托实体运营及产业投资平台协同拓展创新药业务。您的建议已转达公司管理层，重大投资将严格履行内部决策及信息披露义务。创新药研发及投资存在不确定性，敬请注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800028470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","159992","BK1161","BK1574","688739","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652663406","title":"成大生物(688739.SH)：流感病毒裂解疫苗(高剂量)进入I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2652663406","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652663406?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:46","pubTimestamp":1784278000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，成大生物 发布公告，近日，公司全资子公司成大生物(本溪)有限公司研发的流感病毒裂解疫苗(高剂量)已获得国家药品监督管理局临床试验批准并完成I期临床试验全部筹备工作，正式进入I期临床试验阶段。本次流感病毒裂解疫苗(高剂量)启动I期临床试验，表明该产品研发取得阶段性进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","BK0239","688739","159646","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791516342744,"stockEarnings":[{"period":"1week","weight":-0.0062},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0519},{"period":"6month","weight":-0.1479},{"period":"1year","weight":-0.2199},{"period":"ytd","weight":-0.1853}],"compareEarnings":[{"period":"1week","weight":-0.0079},{"period":"1month","weight":-0.0326},{"period":"3month","weight":-0.0461},{"period":"6month","weight":-0.0437},{"period":"1year","weight":-0.0183},{"period":"ytd","weight":-0.0395}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"辽宁成大生物股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"23012人(较上一季度减少4.11%)","perCapita":"18097股","listingDate":"2021-10-28","address":"辽宁省沈阳市浑南区新放街1号","registeredCapital":"41645万元","survey":" 辽宁成大生物股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是人用狂犬病疫苗、人用乙脑灭活疫苗。","listedPrice":110},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"成大生物(688739)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供成大生物(688739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"成大生物,688739,成大生物股票,成大生物股票老虎,成大生物股票老虎国际,成大生物行情,成大生物股票行情,成大生物股价,成大生物股市,成大生物股票价格,成大生物股票交易,成大生物股票购买,成大生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"成大生物(688739)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供成大生物(688739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}